Industry Trends

Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials

By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore.  Read More




Sponsors Run to goBalto.com to Size Up Service Providers



By Deb Borfitz

August 24, 2009 | A newly launched website—goBalto.com—is providing the drug development industry with unprecedented intelligence about their would-be partners around the world. Initial response to the site, in beta testing since April, suggests life science companies have been latently hungering for the resource. Membership has been growing at the rate of hundreds per week and now numbers around 5,000, says Jae Chung, goBalto’s founder and CEO. The company went from conception to incorporation in a week, with funding provided by angel investors.

Jae_Chung
Jae Chung
The pharmaceutical industry has been “one of the laggards” when it comes to having some sort of system for rating service providers, says Chung, who describes goBalto as a cross between consumer review sites Yelp and Expedia and the business networking site LinkedIn. In addition to reviewing past external partners, the goBalto user community can identify new ones—by name, region, and specialty—as well as ask questions, post requests for proposals, hold discussions, and collaborate.

The website’s name (I’m sure I don’t need to tell you) is derived from the Siberian Husky sled dog, Balto, who led his team on the final leg of the 1925 serum run to Nome to deliver diphtheria antitoxin.

Up until now, life science companies have located service providers either by word of mouth or time-consuming Internet searches producing a hodgepodge of results. “We can shave close to two months off the process of finding and evaluating vendors,” says Chung. For service providers, notably clinical research organizations, goBalto is also a convenient way to “stand out from the crowd.”

Although not its original intention, Chung says goBalto is also being used by service providers to rate pharmaceutical companies on the quality of their outsourcing teams. But the bulk of inquiries, up to 50 a day, are being generated by sponsors. About 30% of the overall user base resides in the U.S., another 30% in Europe, and the rest in Asia.

A combination of community policing and algorithms that flag excessive positive or negative reviews prevent ratings from being skewed. Multiple ratings help companies identify patterns. Anonymous ratings are forbidden.

The online directory of service providers includes close to 10,000 companies spanning more than 500 service categories, including all 2,000 or so CROs operating worldwide, says Chung. The site was initially seeded with close to 7,000 companies, most of which the goBalto staff found after an “excruciating” four months scouring the Internet. Another 3,000 companies added themselves. Proprietary lists and reviews of CROs by Pharma Services Network, ChinaBio, and Maya Clinicals are also part of the database.

The “engagement” piece of goBalto needs the most work, says Chung, adding that companies currently communicate primarily by email or teleconference. goBalto is experimenting with activity feeds, to help members keep up to date on opportunities, answers, resources, and company ratings. It also recently rolled out a discussion thread feature on its email system, allowing multiple contacts to keep a history of their discussion and send documents to each other. That could facilitate collaborative project management, he adds.

Self-described “net market makers” that attempted to blend community, content, and commerce a decade ago eventually went belly up. But goBalto, under Chung’s leadership, could be a winner if the revenue structure pans out. In 2002, Chung founded contract biopharmaceutical group Celltrion. The company is currently listed on the Korean KOSDAQ with a market capitalization of $1.6 billion.

Beta testing of goBalto is expected to conclude early next year. Meanwhile, additional service provider lists will be added to the online directory via partners in Europe and Latin America.

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Life Science Webcasts & Podcasts

medidata podcast #8 Meeting Today’s Challenges in Clinical Trial Supply Management
Sponsored by: Medidata Solutions Worldwide  

Setting up and managing the clinical trial involves many complex procedures. Among the most challenging are planning and executing the logistics of the trial’s clinical supplies. This podcast focuses in depth on the following topics which trace current practices and future evolution of this crucial aspect of clinical trials:

  • Current practices in clinical trial logistics
  • Comparing advances in clinical supply practices to  other aspects of clinical trials 
  • Where current practices fall short of meeting the challenges
  • Trends and evolving improvements that may change the way logistics are conducted

Listen Now  


More Podcasts

Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 





Sponsored Links

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .